Mester S, Chan C, Lustig M, Foss S, Jansen JHM, Leangen Herigstad M, Evers M, Nilsen J, Reiding KR, A Damen JM, Burger R, Grevys A, Dalhus B, Valerius T, Sandlie I, Leusen JHW, Andersen JT(2025) Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-life PNAS Nexus, 4(2), pgaf042 DOI 10.1093/pnasnexus/pgaf042, PubMed 40041621
Bashour H, Smorodina E, Pariset M, Zhong J, Akbar R, Chernigovskaya M, Lê Quý K, Snapkow I, Rawat P, Krawczyk K, Sandve GK, Gutierrez-Marcos J, Gutierrez DN, Andersen JT, Greiff V(2024) Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developability Commun Biol, 7(1), 922 DOI 10.1038/s42003-024-06561-3, PubMed 39085379
Foss S, Sakya SA, Aguinagalde L, Lustig M, Shaughnessy J, Cruz AR, Scheepmaker L, Mathiesen L, Ruso-Julve F, Anthi AK, Gjølberg TT, Mester S, Bern M, Evers M, Bratlie DB, Michaelsen TE, Schlothauer T, Sok D, Bhattacharya J, Leusen J, Valerius T, Ram S, Rooijakkers SHM, Sandlie I, Andersen JT(2024) Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria Nat Commun, 15(1), 2007 DOI 10.1038/s41467-024-46321-9, PubMed 38453922
